Genetically engineered CD4 and CD8 T cells: Phase II

CEGE said that 4 of 5 patients tested for virus harbored in gastrointestinal lymphoid tissue had decreased levels of HIV in this reservoir after treatment with its T cell gene therapy. The genetically modified immune cells persisted for at least 100 days after infusion. Results were presented at the World AIDS Conference in Geneva. ...